Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Котов С.В., Исакова Е.В., Чатаева Г.С., Прохорова Н.В. Актинол мемантин в лечении больных ишемическим инсультом. Психиатрия и психофармакотерапия. 2005; 7 (7): 343–5. / Kotov S.V., Isakova E.V., Chataeva G.S., Prokhorova N.V. Aktinol memantin v lechenii bol'nykh ishemicheskim insul'tom. Psyсhiatry and Psychopharmacotherapy. 2005; 7 (7): 343–5. [in Russian] 2. Осадший Ю.Ю., Арчаков Д.С., Тараканова Е.А., Вобленко Р.А. Рандомизированное простое слепое плацебо-контролируемое исследование мемантина как дополнительного средства для лечения негативных симптомов при параноидной шизофрении. Соврем. терапия психических расстройств. 2015; 3: 2–7. / Osadshii Iu.Iu., Archakov D.S., Tarakanova E.A., Voblenko R.A. Randomizirovannoe prostoe slepoe platsebo-kontroliruemoe issledovanie memantina kak dopolnitel'nogo sredstva dlia lecheniia negativnykh simptomov pri paranoidnoi shizofrenii. Sovrem. terapiia psikhicheskikh rasstroistv. 2015; 3: 2–7. [in Russian] 3. Arumugham SS, Reddy JY. Augmentation strategies in obsessive-compulsive disorder. Expert Rev Neurother 2013; 13 (2): 187–202. 4. Bakhla AK, Verma V, Soren S et al. An open-label trial of memantine in treatment-0resistant obsessive-compulsive disorder. Ind Psychiatry J 2013; 22 (2): 149–52. 5. Biederman J, Fried R, Tarko L et al. Memantine in the Treatment of Executive Function Deficits in Adults With ADHD: A Pilot-Randomized Double-Blind Controlled Clinical Trial. J Atten Disord 2014; pii: 1087054714538656. 6. Brennan BP, Roberts JL, Fogarty KV et al. Memantine in the treatment of binge eating disorder: an open-label, prospective trial. Int J Eat Disord 2008; 41 (6): 520–6. 7. Bresink I, Danysz W, Parsons CG et al. Different binding affinities of NMDA receptor channel blockers in various brain regions-indication of NMDA receptor heterogeneity. Neuropharmacology 1995; 34 (5): 533–40. 8. Brown GD, Muzyk AJ, Preud'homme XA. Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine. J Psychiatr Pract 2016; 22 (2): 128–32. 9. Canitano R. New experimental treatments for core social domain in autism spectrum disorders. Front Pediatr 2014; 2: 61. 10. Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006; 40 (2): 344–6. 11. Carrey N, MacMaster F, Sparkes S et al. Glutamatergic changes with treatment in attention deficit hyperactivity disorder: A preliminary case series. J Child Adolesc Psychopharmacol 2002; 12 (4): 331–6. 12. Castle D, Bosanac P, Rossell S. Treating OCD: what to do when first-line therapies fail. Australas Psychiatry 2015; 23 (4): 350–3. 13. Caudron M, Rolland B, Deheul S et al. Catatonia and cannabis withdrawal: A case report. Subst Abus 2016; 37 (1): 188–9. 14. Chez M, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. J Child Neurol 2007; 22 (5): 574–9. 15. Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders. CNS Spectrums 2005; 10 (10): 820–30. 16. Cummings JL, Schneider E, Tariot PN et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil tre-atment. Neurology 2006; 67 (1): 57–63. 17. Day J, Zienius K, Gehring K et al. Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. Cochrane Database Syst Rev 2014; 12: CD011335. 18. De Chiara L, Serra G, Koukopoulos AE et al. Memantine in the treatment and prophylaxis of bipolar type II mood disorder and co-morbid eating disorder: a case report. Riv Psichiatr 2014; 49 (4): 192–4. 19. Erickson C, Posey D, Stigler K et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 2007; 191 (1): 141–7. 20. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007; 30 (3): 136–44. 21. Feusner JD, Kerwin L, Saxena S et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 2009; 42 (1): 81–93. 22. Ghaleiha A, Asadabadi M, Mohammadi MR et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2013; 16 (4): 783–9. 23. Ghaleiha A, Entezari N, Modabbernia A et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 2013; 47 (2): 175–80. 24. Grant J, Chamberlain S, Odlaug B et al. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology 2010; 212 (4): 603–2. 25. Grant JE, Odlaug BL, Schreiber LR, et al. Memantine reduces stealing behavior and impulsivity in kleptomania: a pilot study. Int Clin Psychopharmacol 2013; 28 (2): 106–11. 26. Häge A, Banaschewski T, Buitelaar JK et al. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrumdisorder (ASD) – study protocol for a randomised controlled trial. Trials 2016; 17 (1): 141. 27. Hermanussen M, Tresguerres JA. A new anti-obesity drug treatment: first clinical evidence that, antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders. Econ Hum Biol 2005; 3 (2): 329–37. 28. Hong H, Kim BS, Im HI. Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders. Int Neurourol J 2016; 20 (Suppl. 1): S2–7. 29. Huang CY, Wang LC, Shan YS et al. Memantine Attenuates Delayed Vasospasm after Experimental Subarachnoid Hemorrhage via Modulating Endothelial Nitric Oxide Synthase. Int J Mol Sci 2015; 16 (6): 14171–80. 30. Ishikawa I, Shinno H, Ando N et al. The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer's disease. Acta Neuropsychiatr 2016; 28 (3): 157–64. 31. Iwamoto K, Ikeda K, Mizumura S et al. Combined treatment of methylprednisolone pulse and memantine hydrochloride prompts recovery from neurological dysfunction and cerebral hypoperfusion in carbon monoxide poisoning: a case report. J Stroke Cerebrovasc Dis 2014; 23 (3): 592–5. 32. Jiang SX, Zheng RY, Zeng JQ et al. Reversible inhibition of intracellular calcium influx through NMDA receptors by imidazoline I(2) receptor antagonists. Eur J Pharmacol 2010; 629 (1–3): 12–9. 33. Joshi G, Wozniak J, Faraone SV et al. A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder. J Clin Psychopharmacol 2016; 36 (3): 262–71. 34. Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat 2015; 11: 2883–5. 35. Koola MM. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine. Schizophr Res Cogn 2016; 4: 4–9. 36. Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect 1993; 6 (1): 63–72. 37. Koukopoulos A, Serra G, Koukopoulos AE et al. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord 2012; 136 (1–2): 163–6. 38. Kumar H, Sharma B. Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats. Brain Res Bull 2016; 124: 27–39. 39. Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis 2016; 5 (1): 29–51. 40. Laver K, Dyer S, Whitehead C et al. Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open 2016; 6 (4): e010767. 41. Lee SY, Chen SL, Chang YH et al. Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. J Psychiatr Res 2013; 47 (10): 1343–8. 42. Lee SY, Chen SL, Chang YH et al. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial. J Clin Psychopharmacol 2014; 34 (3): 337–43. 43. Lehmann A, Kärrberg L. Effects of N-methyl-D-aspartate receptor antagonists on cisplatin-induced emesis in the ferret. Neuropharmacology 1996; 35 (4): 475–81. 44. Lenze EJ, Skidmore ER, Begley AE et al. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry 2012; 27 (9): 974–80. 45. Matsuda Y, Kishi T, Iwata N. Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials. J Psychiatr Res 2013; 47 (12): 2018–20. 46. Maurice T. Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments. Behav Brain Res 2016; 296: 270–8. 47. Minkeviciene R, Banerjee P, Tanila H. Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology 2008; 54 (7): 1079–85. 48. Mohammadi MR, Mohammadzadeh S, Akhondzadeh S. Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial. Iran J Psychiatry 2015; 10 (2): 106–14. 49. Mori E. How Treatable is Vascular Dementia? [Article in Japanese]. Brain Nerve 2016; 68 (4): 441–50. 50. Muhonen LH, Lahti J, Sinclair D et al. Treatment of alcohol dependence in patients with co-morbid major depressive disorder-predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy 2008; 3: 20. 51. Nandhra HS, Murphy CL, Sule A.Novel pharmacological agents targeting memory and cognition in the treatment of anxiety disorders. Hum Psychopharmacol 2013; 28 (6): 538–43. 52. Noruzzadeh R, Modabbernia A, Aghamollaii V et al. Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study. Headache 2016; 56 (1): 95–103. 53. Obregon DF, Velasco RM, Wuerz TP et al. Memantine and catatonia: a case report and literature review. J Psychiatr Pract 2011; 17 (4): 292–9. 54. Olivan-Blázquez B, Herrera-Mercadal P, Puebla-Guedea M et al. Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up. Pain 2014; 155 (12): 2517–25. 55. Omranifard V, Rajabi F, Mohammadian-Sichani M. et al. The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, double-blind, controlled, clinical trial. Adv Biomed Res 2015; 4: 211. 56. Osborne NN, Beale R, Golombiowska-Nikitin K et al. The effect of memantine on various neurobiological processes. Arzneimittelforschung 1982; 32 (10): 1246–55. 57. Ota H, Ogawa S, Ouchi Y et al. Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. Exp Gerontol 2015; 72: 109–16. 58. Owley T, Salt J, Guter S et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psy-chopharmacol 2006; 16 (5): 517–24. 59. Peeters M, Romieu P, Maurice T et al. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004; 19 (8): 2212–20. 60. Pekrul SR, Fitzgerald KD. Memantine Augmentation in a Down's Syndrome Adolescent with Treatment – Resistant Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol 2015; 25 (7): 593–5. 61. Pickering G, Morel V, Joly D et al. Prevention of post-mastectomy neuropathic pain with memantine: study protocol for a randomized controlled trial. Trials 2014; 15: 331. 62. Pikwer A. Depersonalization disorder may be related to glutamate receptor activation imbalance. Med Hypotheses 2011; 77 (4): 593–4. 63. Ramaswamy S, Madabushi J, Hunziker J et al. An Open-Label Trial of Memantine for Cognitive Impairment in Patients with Posttraumatic Stress Disorder. J Aging Res 2015; 2015: 934162. 64. Rammes G, Rupprecht R, Ferrari U et al. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001; 306 (1–2): 81–4. 65. Rapp A, Dodds A, Walkup JT, Rynn M. Treatment of pediatric anxiety disorders. Ann N Y Acad Sci 2013; 1304: 52–61. 66. Rodriguez CI, Levinson A, Zwerling J et al. Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion. J Clin Psychiatry 2016; 77 (5): 688–9. 67. Rogawski MA. What is the rationale for new treatment strategies in Alzheimer's disease? CNS Spectr 2004; 9 (7 Suppl. 5): 6–12. 68. Rossignol DA, Frye RE. The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review. Front Pediatr 2014; 2: 87. 69. Schaefer M, Leopold K, Hinzpeter A et al. Memantine-associated reversal of clozapine-induced weight gain. Pharmacopsychiatry 2007; 40 (4): 149–51. 70. Schwartz TL, Siddiqui UA, Raza S. Memantine as an augmentation therapy for anxiety disorders. Case Rep Psychiatry 2012; 2012: 749796. 71. Serra G, De Chiara L, Koukopoulos A et al. Antimanic and long-lasting mood stabilizing effect of memantine in bipolar I mood disorder: two case reports. J Clin Psychopharmacol 2013; 33 (5): 715–7. 72. Serra G, De Chiara L, Koukopoulos AE et al. Memantine in the treatment and prophylaxis of bipolar II disorder and comorbid fibromyalgia: a case report. J Psychiatr Pract 2014; 20 (3): 232–6. 73. Serra G, De Chiara L, Manfredi G et al. Memantine in the management of affective recurrences of bipolar disorders after the discontinuation of long-term lithium treatment: three case histories. Ther Adv Psychopharmacol 2014; 4 (1): 53–5. 74. Serra G, Koukopoulos A, De Chiara L et al. Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder. J Clin Psychiatry 2015; 76 (1): e91–7. 75. Shim SS, Nadeem R. Are NMDA receptor antagonists beneficial in the treatment of schizophrenia? J Psychiatr Res 2014; 51: 19–20. 76. Sierra M. Depersonalization: A New Look at a Neglected Syndrome. 1st Ed. Cambridge Medicine, 2012. 77. Simeon D, Abugel J. Feeling Unreal: Depersonalization Disorder and the Loss of the Self. 1st Ed. Oxford University Press, 2008. 78. Smith EG, Deligiannidis KM, Ulbricht CM et al. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2013; 74 (10): 966–73. 79. Smith KL, Rao RR, Velázquez-Sánchez C et al. The uncompetitive N-methyl-D-aspartate antagonist memantine reduces binge-like eating, food-seeking behavior, and compulsive eating: role of the nucleus accumbens shell. Neuropsychopharmacology 2015; 40 (5): 1163–71. 80. Somer E, Amos-Williams T, Stein DJ. Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD). BMC Psychol 2013; 1 (1): 20. 81. Spilman P, Descamps O, Gorostiza O et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. Brain Res 2014; 1551: 25–44. 82. Stahl SM, Muntner N. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th Ed. Cambridge University Press, 2013. Полный список литературы можно посмотреть на нашем сайте в Интернете: www.con-med.ru 83. Stinton C, McKeith I, Taylor JP et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry 2015; 172 (8): 731–42. 84. Ströhle A, Schmidt DK, Schultz F et al. Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials. Am J Geriatr Psychiatry 2015; 23 (12): 1234–49. 85. Strzelecki D, Tabaszewska A, Barszcz Z et al. A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life. Psychiatry Investig 2013; 10 (4): 421–4. 86. Veerman SR, Schulte PF, Smith JD et al. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med 2016; p. 1–13. 87. Weller M, Kornhuber J. Pathophysiology and therapy of malignant neuroleptic syndrome. [Article in German]. Nervenarzt 1992; 63 (11): 645–55. 88. Wilkins LK, Girard TA, Cheyne JA. Anomalous bodily-self experiences among recreational ketamine users. Cogn Neuropsychiatry 2012; 17 (5): 415–30. 89. Williams K, Dattilo M, Sabado TN et al. Pharmacology of delta2 glutamate receptors: effects of pentamidine and protons. J Pharmacol Exp Ther 2003; 305 (2): 740–8. 90. Zhao Y, Navia BA, Marra CM et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials 2010; 11 (1): 59–67.